| Title |
Tislelizumab (TIS) plus chemotherapy (chemo) for EGFR-mutated non-squamous non-small cell lung cancer (nsq-NSCLC) failed to EGFR tyrosine kinase inhibitors (TKIs) therapies: the primary analysis |
| Description |
Abstract publication for ESMO IO 2022. Treatment option is limited for EGFR-mutated NSCLC after failure to EGFR TKIs. This multicenter, open-label, phase II study aims to evaluate the efficacy and safety of TIS plus chemo (cohort 1) or TIS plus chemo and bevacizumab (cohort 2) in EGFR-mutated nsq-NSCLC pts failed to EGFR TKI therapies. Herein, the primary analysis of cohort 1 is reported. |
| Organism |
Homo |
| Data Type |
Other Type of Genomic Data |
| Data Accessibility |
Controlled-access |
| BioProject |
PRJCA012011 |
| Release Date |
2026-01-30 |
| Submitter |
hui han (hanxkyy@aliyun.com) |
| Organization |
Shanghai Chest Hospital |
| Submission Date |
2022-09-20 |